MDR Article 1(2) · Annex XVI · Regulations 2022/2346 and 2022/2347
Annex XVI devices under the MDR
No medical purpose. No regulatory shortcut.
A coloured contact lens, a dermal filler and a brain-stimulation headset may be sold for very different reasons. The MDR sees the common thread: technology that interacts with the body and can create risks comparable to those of a medical device.
Open the regulatory case ↓No diagnosis · no treatment · no prevention claim
MDR controls engaged
The regulatory paradox
The claim may be cosmetic. The harm is still physical.
Annex XVI does not pretend that an aesthetic product has a medical purpose. It does something more precise. It brings six defined product groups under the MDR because their functioning and risks justify medical-device-level controls.
The result is not “MDR-lite”. Qualification, classification, common specifications, technical documentation, clinical evidence, conformity assessment and post-market duties form one connected system.
01
A product does not need to treat disease to create medical-device risk #
Cosmetic contact lenses can injure the cornea. Fillers can cause vascular occlusion or infection. Energy-based equipment can burn, scar or alter pigmentation. Brain stimulation can change neuronal activity. Removing the therapeutic claim does not remove the biological interaction.
Article 1(2) of the MDR therefore extends the Regulation to the product groups listed in Annex XVI from the date the relevant common specifications apply. The legal trigger is not a vague resemblance to healthcare. The product must fit the wording of an Annex XVI group and the scope of the corresponding common specifications.
Diagnosis, prevention, monitoring, treatment or another medical purpose
Aesthetic appearance, body modification or another listed non-medical effect
“Aesthetic product” is not itself a legal category. Some aesthetic products fall within Annex XVI, some remain cosmetics or general consumer products, and some are medical devices because their intended purpose is medical.
02
Six doors lead into Annex XVI #
The list is technology- and purpose-specific. It is not an open invitation to regulate every beauty product as a device. Each door has boundaries, inclusions and exclusions.
Contact lenses or other items intended to be introduced into or onto the eye.
Surgically invasive products for modifying anatomy. Annex XVI also names fixation, while the current common-specification scope excludes it.
Substances, combinations or items introduced for facial, dermal or mucous-membrane filling, excluding tattooing.
Equipment used to reduce, remove or destroy adipose tissue, including liposuction, lipolysis and lipoplasty systems.
Lasers, IPL and other high-intensity electromagnetic radiation equipment for specified skin treatments.
Non-invasive equipment using electrical, magnetic or electromagnetic fields that penetrate the cranium.
Details matter. Sunbeds are excluded from the group 5 common specifications. Mesotherapy products fall within group 3 only when their intended purpose includes filling. A laser that removes fat and tightens skin may enter both groups 4 and 5, with the relevant requirements applying cumulatively.
03
Qualification starts with the exact product story #
Do not begin by forcing the product into a risk class. First establish whether it qualifies as an Annex XVI product at all. Read the intended purpose, technology, mechanism, body interaction, user, treatment setting and promotional claims against both the Annex XVI wording and the scope section of Regulation 2022/2346.
Define the non-medical effect precisely across labelling, instructions, website and sales material.
Map energy, material, invasiveness, tissue interaction, duration and accessories.
Test every element against Annex XVI and the applicable common-specification scope.
Dual purpose raises the bar
A device with both medical and non-medical intended purposes must cumulatively fulfil the requirements applicable to both. Where the rules point in different directions, the more stringent requirement may govern. Claims cannot be split into convenient regulatory fragments when the same product and risk controls support both uses.
04
Qualification opens the door. Classification decides the route. #
Once the product qualifies, apply the MDR classification rules in Annex VIII and, for certain active groups, Implementing Regulation 2022/2347. Classification is product-specific, but the following pattern shows why a blanket “aesthetic products are low risk” assumption fails.
IIa or IIb
Duration of use under Rule 5IIb or III
Implantable, absorbable and specific Rule 8 featuresIIb or III
Implantation, absorption, biological effect or incorporated substanceIIb
Reclassification under Regulation 2022/2347IIa or IIb
Hair-removal-only equipment is IIa, other covered skin treatment is IIbIII
Reclassification under Regulation 2022/2347Components can follow a different rule from the main equipment. Reusable surgical instruments, cannulas and connecting tubes are examples where the classification analysis must be performed at the level of the actual device, not copied from the headline group.
Notified-body involvement follows the applicable MDR class and conformity route. It is common for Annex XVI products, but it should be concluded from classification rather than treated as an automatic premise.
05
Common specifications turn broad MDR principles into product controls #
Implementing Regulation 2022/2346 has one common layer for all six groups and dedicated annexes for each group. It applies from 22 June 2023. The text does more than name hazards. It connects risk management, design controls, information for safety, consumer communication and post-production evidence.
Lifecycle process, trained personnel, traceability and explicit acceptability criteria
Group-specific controls for biological, mechanical, energy and use-related hazards
Qualifications, exclusions, treatment context, foreseeable misuse and emergency action
Expected performance, residual risks, follow-up, warnings and plain-language material
Complaints, clinical data, new hazards, trend signals and corrective action
The common specifications must be applied together with the rest of the MDR. They do not replace Annex I GSPRs, the QMS, technical documentation, economic-operator obligations, UDI, PMS, vigilance or the applicable conformity-assessment procedure.
06
No clinical benefit does not mean no clinical evidence #
For Annex XVI products, the MDR requirement to demonstrate clinical benefit is understood as a requirement to demonstrate performance. The clinical evaluation is based on relevant safety data, including PMS, PMCF and, where applicable, a specific clinical investigation.
This changes the centre of gravity of the evidence package. The manufacturer must prove that the promised non-medical effect is achieved and that the associated risk remains acceptable, even though no therapeutic benefit is being claimed.
What visible, physical or functional effect does the manufacturer promise?
Who uses it, on whom, how often, in what environment and with which foreseeable errors?
What harms occur, how often, how severe are they and how effective are the controls?
How will PMS and PMCF confirm that the pre-market conclusions remain valid?
Equivalence is a demanding route
Regulation 2022/2346 allows analogous devices with a medical purpose to inform the analysis, but similarity is not a shortcut around access to data, technological comparison, biological comparison and clinical relevance. A neighbouring technology can illuminate risk without proving equivalence.
07
Without medical benefit, risk has nowhere to hide #
A therapeutic device may justify residual risk against expected clinical benefit. A product used only for an aesthetic or other non-medical purpose cannot rely on that same argument. The common specifications require risks to be eliminated or reduced as far as possible and set a deliberately demanding approach to acceptability.
Start with inherent safety in design and manufacturing.
Control what cannot reasonably be eliminated.
Use warnings and training after stronger controls have been considered.
Confirm that one control has not created a different, greater risk.
Risk analysis must include normal and fault conditions, foreseeable misuse, user competence, consumer characteristics and the use environment. For lay use, the distance between a technically correct instruction and actual behaviour becomes a design input.
08
The consumer must see more than the promise #
A glamorous claim can fit in six words. An informed decision needs more. The common specifications require the non-medical purpose, expected performance, residual risks and relevant follow-up to be made visible in a form suited to users and consumers.
A clear description of the effect the product is intended to achieve
Describe the non-medical effect in understandable terms.
Explain risks, side effects and their control measures clearly.
State excluded consumer groups, contraindications and special conditions.
Give lifetime or resorption information, follow-up and escalation instructions.
Information supplied for a solely non-medical purpose must not carry a clinical-benefit claim. For some product groups, the user must provide a plain-language annex to the consumer before treatment. Training requirements and professional-use restrictions must also be translated into actual distribution and use controls.
09
CE marking is the output of a complete MDR system #
Once in scope, the product enters the MDR machinery. The manufacturer needs more than a risk report and a test certificate. The regulatory system must connect the organisation, product evidence, supply chain and post-market feedback.
Responsibilities, suppliers, production, change and CAPA
Device definition, GSPRs, verification, validation and evidence
Performance, safety, investigations and PMCF strategy
Economic operators, registration, UDI, label and declaration
PMS, vigilance, trend reporting and corrective action
Class-based route and notified-body involvement where required
- Freeze the intended purpose, claims, users and product boundary
- Document Annex XVI qualification and all applicable common-specification scopes
- Classify every device and accessory using Annex VIII and Regulation 2022/2347
- Map GSPRs and common specifications into design and evidence requirements
- Build clinical, usability, biological, technical and safety evidence around real use
- Align QMS, technical documentation and post-market plans with the conformity route
- Confirm notified-body scope and capacity where third-party assessment is required
- Release only when labelling, operators, registration and surveillance are connected
10
Transition dates are conditional routes, not blanket extensions #
The common specifications apply from 22 June 2023. Regulation 2022/2346, as amended by Regulation 2023/1194, creates specific transition routes for certain products already lawfully marketed before that date. The applicable end date depends on the evidence and conformity-assessment route.
No significant change in design or intended purpose
The staged conditions include a started clinical investigation and, from 2028, a written notified-body agreement.
Where notified-body involvement is required, a written agreement is needed from 1 January 2027.
A separate route may apply when the detailed Article 2(3) and MDR Article 120 conditions are met.
A new product placed on the market after the common specifications became applicable does not inherit these routes merely because development started earlier. Nor does a transition end date excuse a significant change, a missed milestone or the absence of an eligible pre-2023 market history.
Build a dated transition memo for each product. Record the qualifying history, selected route, milestones, significant-change controls, notified-body evidence and the exact provision relied upon.
Official sources
- Regulation (EU) 2017/745 on medical devices
- Consolidated Implementing Regulation (EU) 2022/2346 on common specifications
- Implementing Regulation (EU) 2022/2347 on reclassification
- Implementing Regulation (EU) 2023/1194 on transitional provisions
- MDCG 2023-5 guidance on qualification and classification of Annex XVI products
- European Commission overview for manufacturers of devices without an intended medical purpose
The regulatory outcome
A non-medical purpose changes the evidence question, not the need for control
Annex XVI products sit in an unusual category, but their route is not mysterious. Define the product precisely, qualify it against the legal scope, classify it correctly, then connect common specifications with the full MDR lifecycle.
The most difficult dossiers are rarely defeated by one missing test. They fail when claims, risk, performance, user information and post-market plans describe different products.
Different purpose. Comparable risk. One coherent MDR story.
Annex XVI regulatory strategy
Need to turn an aesthetic product into a defensible MDR pathway?
Discuss your product ↗From the knowledge centre
